P&G buys in to Aryx therapy
Procter & Gamble has inked a development deal with Aryx Therapeutics for Aryx's gastrointestinal disorder drug. Aryx gets $25 million up front for the licensing deal on ATI-7505, with total payments for a successful commercial launch adding up to $435 million. Aryx retains an option to co-develop and promote the therapy.
- here's the AP report on the licensing deal
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets